Humana Inc (HUM) Stake Lifted by Bessemer Group Inc.
Bessemer Group Inc. increased its holdings in shares of Humana Inc (NYSE:HUM) by 436.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 891 shares of the insurance provider’s stock after acquiring an additional 725 shares during the period. Bessemer Group Inc.’s holdings in Humana were worth $221,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. WFG Advisors LP lifted its holdings in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after purchasing an additional 20 shares in the last quarter. Advantus Capital Management Inc lifted its holdings in Humana by 1.4% in the 3rd quarter. Advantus Capital Management Inc now owns 14,798 shares of the insurance provider’s stock valued at $3,605,000 after purchasing an additional 203 shares in the last quarter. Cadence Capital Management LLC lifted its holdings in Humana by 3.6% in the 3rd quarter. Cadence Capital Management LLC now owns 5,887 shares of the insurance provider’s stock valued at $1,434,000 after purchasing an additional 205 shares in the last quarter. Daiwa SB Investments Ltd. lifted its holdings in Humana by 44.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after purchasing an additional 220 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in Humana by 3.6% in the 3rd quarter. Mackenzie Financial Corp now owns 6,642 shares of the insurance provider’s stock valued at $1,618,000 after purchasing an additional 232 shares in the last quarter. Hedge funds and other institutional investors own 94.13% of the company’s stock.
Shares of Humana Inc (NYSE HUM) opened at $267.47 on Thursday. Humana Inc has a 52 week low of $203.36 and a 52 week high of $293.35. The stock has a market capitalization of $36,767.10, a price-to-earnings ratio of 16.04, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93. The company has a quick ratio of 1.61, a current ratio of 1.85 and a debt-to-equity ratio of 0.48.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.75%. This is an increase from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. Humana’s dividend payout ratio (DPR) is presently 9.59%.
Humana announced that its Board of Directors has initiated a share repurchase program on Thursday, December 14th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the insurance provider to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
A number of research analysts have weighed in on the company. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $294.00 price objective on the stock in a report on Monday. JPMorgan Chase & Co. raised their price objective on Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a report on Monday. Deutsche Bank raised their price objective on Humana from $259.00 to $270.00 and gave the company a “hold” rating in a report on Friday, February 9th. Oppenheimer raised their price objective on Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Finally, Leerink Swann raised their price objective on Humana from $280.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Humana presently has a consensus rating of “Buy” and a consensus price target of $270.47.
In related news, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the sale, the senior vice president now directly owns 11,704 shares of the company’s stock, valued at approximately $2,901,304.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total value of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The disclosure for this sale can be found here. Insiders have sold a total of 10,115 shares of company stock valued at $2,501,627 over the last three months. Corporate insiders own 0.80% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.